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Abstract
High-altitude pulmonary oedema (HAPE) is a non-cardiogenic form of pulmonary oedema usually occurring 36–72 hours after arrival at
altitudes >2,500–3,000 m in otherwise healthy individuals. Individual predisposition is the most important risk factor for HAPE. In some
cases, this might be related to foetal programming of pulmonary vascular dysfunction involving epigenetic mechanisms. Excessive non-
homogenous hypoxic pulmonary vasoconstriction related to impaired pulmonary nitric oxide synthesis is the major mechanism.
Moreover, defective alveolar fluid clearance related to impaired transepithelial respiratory salt and water transport also has a role.
Immediate descent is the treatment of choice. If descent is not possible, low flow oxygen or a hyperbaric chamber can be used. If oxygen
is unavailable, drugs that lower the pulmonary artery pressure should be administered. If neurologic symptoms develop, dexamethasone
should also be added. HAPE can be prevented by slow, graded ascent (i.e., an increase in the average sleeping altitude >2,500 m by 
<400 m/day). Individuals who are susceptible to HAPE can prevent its reoccurrence by prophylaxis with dexamethasone or nifedipine.
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Pulmonary oedema results from a persistent imbalance between
forces that drive water into the airspace of the lung and the biological
mechanisms needed for its removal.1,2 There is evidence that some
degree of asymptomatic alveolar fluid accumulation might represent
a normal phenomenon in healthy humans shortly after arrival at high
altitude.3,4 In some subjects, however, more severe lung fluid
accumulation occurs and life-threatening high-altitude pulmonary
oedema (HAPE) develops.
After a rapid ascent to 4,559 m in the Alps, approximately 10 % of
mountaineers develop HAPE. This incidence increases to 60–70  % 
in mountaineers who had suffered from HAPE before (HAPE-prone
subjects), demonstrating individual susceptibility to be the most
important determinant of HAPE. HAPE usually develops between 36
and 72 hours after arrival at high altitude. It is rarely observed at
altitudes <2,500 m and after more than five days spent at the same
altitude. The initial symptoms are exaggerated dyspnea on exertion
and cough. As the disease progresses, dyspnea worsens, the cough
can become productive and fever often develops.5,6 A discrepancy
between mild signs at pulmonary auscultation (discrete rales) and
severe clinical symptoms is often observed.
Pathophysiology
Extensive and easily accessible reviews on the pathophysiology of
HAPE have recently been published.2,7–10 Briefly, HAPE results from the
conjunction of defective pulmonary vascular function, leading to
uneven exaggerated hypoxic pulmonary vasoconstriction11 and, in turn,
capillary leaking, as well as defective alveolar fluid clearance related to
defective respiratory transepithelial sodium and water transport. In
HAPE-prone mountaineers, average systolic pulmonary artery pressure
after rapid ascent to 4,559 m is typically approximately 70 mmHg; lung
perfusion scans have provided direct evidence for uneven perfusion
with overperfusion of lung regions with radiological evidence of
pulmonary oedema.12 Bronchoalveolar lavage early after arrival at high
altitude revealed increased erythrocyte counts and large molecular
weight proteins, demonstrating capillary leaking in HAPE-prone
subjects.13 Defective pulmonary nitric oxide (NO) production is a central
mechanism underpinning exaggerated hypoxic pulmonary
vasoconstriction in HAPE-prone subjects. Moreover, and possibly
related to decreased NO bioavailability, exaggerated vasoconstriction
induced by sympathetic overactivity14 and increased endothelin-1
synthesis also have a role.15 Finally, the prevalence of a patent foramen
ovale (PFO) is markedly increased in HAPE-prone subjects.16 By leading
to exaggerated hypoxemia, right-to-left shunting across a PFO can
further facilitate exaggerated hypoxic pulmonary hypertension in 
HAPE-prone subjects. Although these observations show the
pathophysiological importance of pulmonary hypertension in this
setting, in a recent study on foetal/perinatal programming of pulmonary
vascular dysfunction in humans (see below), we found that exaggerated
pulmonary hypertension per se is not always sufficient to trigger HAPE,
and that additional mechanisms have a role.17
In subsequent studies, we then provided direct evidence for the
importance of transepithelial respiratory sodium transport in 
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the pathogenesis of HAPE. In genetically engineered mice, defective
respiratory sodium transport facilitates pulmonary oedema.18 In
HAPE-prone subjects, nasal potential difference, a proxy of
transepithelial respiratory sodium transport, is decreased19 and this
defect is further aggravated at high altitude.20,21 Beta-adrenergic
agonists stimulate alveolar fluid clearance in ex vivo human and rat
lungs.22 Finally, and most importantly, pharmacological stimulation
of this transport with the beta-adrenergic agonist salmeterol
prevents HAPE in susceptible mountaineers.19
Based on these results, we suggested a new concept for the
pathogenesis of HAPE (see Figure 1).
Treatment of High-altitude Pulmonary Oedema
Rapid improvement of oxygenation is the treatment of choice. HAPE
is therefore best managed by descent. When immediate descent is
not possible, low flow oxygen (2–4 l/min) should be administered, if
available. Alternatively, portable hyperbaric chambers (Gamow,
USA; Certec, France), which are lighter to carry than are oxygen
cylinders, can be used. However, there might be a rebound effect on
stopping hyperbaria.
Other treatment options should never be considered as a substitute
for rapid descent (or oxygen administration and/or hyperbaria), but
should be used to improve the clinical condition to facilitate descent
or when descent is impossible and oxygen and/or hyperbaric
chambers are not available. Under these conditions, lowering
pulmonary artery pressure with pharmacological agents is strongly
recommended. Nifedipine (20 mg taken every six hours) improved
symptoms, arterial oxygenation and radiographic appearance in a
small group of mountaineers suffering from HAPE while remaining at
4,559 m.23 Given that impaired NO bioavailability has a central role in
the pathogenesis of HAPE, inhaled NO (40 ppm) has been successfully
used to treat HAPE.24 Despite strong evidence that, during normobaric
and hypobaric hypoxia, phosphodiesterase 5 inhibitors increase NO
bioavailability and decrease pulmonary-artery pressure,25 there are no
clinical trials on the use of these drugs for the treatment of HAPE;
however, anecdotal data suggest that sildenafil is useful in this
situation.26 Interestingly, in this report, dexamethasone – a drug that,
when administered alone, has no beneficial in the treatment of HAPE10
– was co-administered for acute mountain sickness (AMS) symptoms
and might have contributed by tightening pulmonary capillaries and
stimulating alveolar fluid clearance. Moreover, dexamethasone might
have prevented the exacerbation of AMS symptoms by sildenafil, a
major problem associated with the use of these agents at high
altitude.26 Anecdotal reports suggest that lowering of pulmonary
artery pressure with other pharmacological agents (e.g. hydralazine
or phentolamine) also has beneficial effects in HAPE,27 and there is
evidence suggesting that alpha-adrenergic blockade is more potent in
lowering pulmonary artery pressure than are other 
non-specific vasodilators. Although endothelin antagonists and
prostacyclin analogues are effective for the treatment 
of pulmonary hypertension at low altitude and attenuate 
altitude-induced pulmonary hypertension,28 there are no data on their
potential usefulness for the treatment of HAPE. It is noteworthy that
there is no place for the use of diuretics in the treatment of HAPE; not
only do these drugs have no beneficial effects, but they can also
cause serious adverse effects (i.e. severe arterial hypotension and
shock) in already dehydrated subjects. Finally, it is currently unknown
whether the combined regimen of bed rest, supplemental oxygen plus
administration of a pulmonary vasodilator drug is superior to bed rest
and oxygen alone.
Beta-adrenergic agonists, such as salmeterol, stimulate
transepithelial sodium transport and alveolar fluid clearance in
experimental animal models.22 In line with this concept, 
beta-adrenergic stimulation of respiratory transepithelial sodium
transport was subsequently found to decrease extravascular lung
water in patients with acute respiratory distress syndrome (ARDS),29 to
accelerate the resolution of pulmonary oedema after lung resection30
and to have beneficial effects in the treatment of HAPE.31
Prevention of High-altitude Pulmonary Oedema
General Recommendations
High-altitude illness occurs if there is a dysfunction in the adjustments
made by an organism to the acute lowering of the arterial oxygen
content. Three principal factors favour such dysfunction – individual
susceptibility, rapidity of ascent and absolute altitude itself.32 The
major importance of slow ascent is demonstrated by the observation
that mountaineers who repeatedly developed HAPE following rapid
ascent to high altitude in the Alps successfully reached altitudes up to
7,000 m when the average daily ascent rate above 2,000 m did not
exceed 400 m/day.26 Besides these main determinants, additional
factors, such as exposure to cold temperatures, heavy exercise, and
recent or coexisting airway infection, might also facilitate the
occurrence of HAPE.32
Even in the absence of a history of previous HAPE, observation of the
following general principles might help to prevent altitude-related
medical problems (see also Figure 2).
•   Take sufficient time to acclimatise at an intermediate altitude of
2,500 m and avoid raising the average daily sleeping altitude by
>400 m thereafter.
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Figure 1: A New Concept for the Pathogenesis of 
High-Altitude Pulmonary Oedema
Genetic impairment of the
transepithelial sodium transport
Sympathetic
overactivity
PFO Endothelial
dysfunction
Hypothermia Hypoxia
Impaired respiratory
transepithelial sodium transport
Acquired impairment of
alveolar fluid clearance
Augmented alveolar
fluid flooding
Exaggerated hypoxic
pulmonary hypertension
HAPE
Pulmonary oedema results from a persistent imbalance between the forces that drive water
into the airspace and the biological mechanisms responsible for its removal. In high-altitude
pulmonary oedema (HAPE)-prone subjects, alveolar fluid flooding is increased because of
uneven exaggerated pulmonary vasoconstriction that is related, at least in part, to defective
nitric oxide bioavailability and exaggerated sympathetic activation. Exaggerated pulmonary
hypertension per se, however, is not sufficient to trigger HAPE. HAPE-prone subjects are
also characterised by a defect of the respiratory transepithelial sodium and water transport,
which, during high-altitude exposure, might be further impaired by environmental factors
such as hypoxia and cold temperature. The conjunction of these pulmonary vascular
endothelial and alveolar epithelial defects ultimately leads to HAPE.
PFO = patent foramen ovale.
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•   A high carbohydrate diet increases the respiratory quotient and
might improve oxygen use.
•   Avoid alcohol and hypnotic drugs that might impair the hypoxic
ventilatory response.
•   When arriving at high altitude, avoid unnecessary exertion,
because it potentiates the pulmonary vasoconstriction.
•   Drink plenty of fluids during the stay at high altitude.
Prevention of exaggerated pulmonary hypertension
Pharmacological prevention of exaggerated pulmonary hypertension
in HAPE-prone subjects reduces the incidence of pulmonary oedema
during high-altitude exposure when slow ascent is not possible.33,34
Sustained release nifedipine (20 mg slow release three times daily)
started on the day before ascent and continued during the first three to
five days after ascent, significantly reduced the incidence of exaggerated
pulmonary hypertension and pulmonary oedema in HAPE-prone
subjects.26,33 More recently, increasing NO bioavailability with the
phosphodiesterase-5 inhibitor tadalafil had similar beneficial effects that
came, however, at the cost of severe AMS in some of the participants.34
Although dexamethasone has no beneficial effects in the treatment of
HAPE10, when taken one day prior to ascent (but not if taken after the first
night) at 4,559 m, a recent study showed that the drug prevented
pulmonary hypertension and pulmonary oedema in HAPE-prone
subjects.34 The mechanism is unknown, but because dexamethasone
prevents insulin- and alcohol-induced sympathetic activation in humans
by a central neural mechanism,35,36 it is tempting to speculate that its
beneficial effects are related to the prevention of exaggerated 
hypoxia-induced sympathetic vasoconstriction in HAPE-prone subjects.
Alternatively, stimulation of alveolar transepithelial sodium and water
transport, and tightening of the pulmonary capillary endothelium by
inhibition of hypoxia-induced inflammation, and improvement of
surfactant production might also have a role. 
Stimulation of Transepithelial Sodium Transport 
and Alveolar Fluid Clearance
To examine the importance of defective respiratory sodium transport
in the pathogenesis of HAPE, we studied whether pharmacological
stimulation of this transport decreases the incidence of HAPE in
susceptible subjects. We found that prophylactic stimulation of this
transport with salmeterol decreased the incidence of high-altitude
pulmonary oedema in highly susceptible subjects by more than
50 %.19 Salmeterol appears to be slightly less effective than drugs that
prevent exaggerated pulmonary hypertension (i.e. nifedipine, tadalafil
and dexamethasone), suggesting that prevention of the excessive
increase in pulmonary–artery pressure is possibly more effective than
stimulation of alveolar fluid clearance. Whether the combination of a
pulmonary vasodilator and a beta-adrenergic agonist has synergic
effects in the prevention or HAPE has not yet been investigated.
Currently, and in the absence of contraindications (e.g., glucose
intolerance), dexamethasone has possibly the most attractive profile,
because it is also highly efficient for the prophylaxis of AMS that is
often also present in patients suffering from HAPE.
Prediction of HAPE susceptibility
Prediction of HAPE susceptibility in individuals without previous 
high-altitude exposure represents one of the most challenging
problems in high-altitude medicine. Although a history of previous
HAPE (see above) or AMS in adults37 is highly valuable to predict the
risk and take adequate preventive measures during future exposure,
there currently exists no validated test or battery of tests at low
altitude that can be used to predict the risk of high-altitude illness in
healthy subjects with no previous exposure.
Simulated Altitude Exposure
Pulmonary–artery pressure in HAPE-prone subjects is normal and not
different from that of HAPE-resistant subjects at low altitude.38 Based
on this observation, studies have examined whether pulmonary–artery
pressure responses to hypoxia, or whether hypoxia plus exercise can
be used to identify individuals at risk for HAPE. A recent study
examining HAPE-prone and HAPE-resistant mountaineers suggested
that measurement of pulmonary–artery pressure during normoxic
exercise or short-term exposure to hypoxia could be used to identify
individuals at risk,38 even though there existed an overlap in the
pulmonary vascular responses between the two groups. This study
suggested that the limit of a normal systolic pulmonary–artery
pressure response to normoxic exercise or acute exposure to hypoxia
(equivalent to an altitude of 4,500 m) was approximately 40 mmHg.
Based on this study, in a recent small prospective trial, seven out of
29 subjects with a pulmonary–artery pressure >40 mmHg, but none 
of 24 individuals with a response <40 mmHg, developed HAPE during
a two-night stay at 4,559 m. This suggests that a negative test
(pulmonary artery systolic pressure [PASP]<40 mmHg) enables one to
rule out HAPE (negative predictive value 97 %) whereas a positive test
has little predictive value (positive predictive value of 56 %).39 Whether
the positive predictive value of this test could be increased by the
combination of other measurements, such as the nasal potential
difference20 or the hypoxic ventilatory drive,40 is not known.
Genetic Predisposition
There is some evidence to suggest that, in some populations,
endothelial NO synthase (eNOS) polymorphisms associated with
impaired vascular NO synthesis contribute to HAPE susceptibility,41,42
whereas eNOS polymorphisms associated with increased NO
synthesis confer protection against HAPE.43 However, these
observations have no practical implications for the prediction of HAPE
susceptibility in the general population so far.
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Figure 2: Recommendations for Prevention and
Treatment of High-Altitude Pulmonary Oedema
HAPE
Prevention Treatment
Without AMS
With AMS AddAdd
• Slow ascent (<400 m/day)
• Dexamethasone (4 mg 
   every 6 h)
• Nifedipine (30–60 mg/day,
   start 24 h before ascent) if
   dexamethasone 
   contraindicated
• Acetazolamide (125 mg 
   every 12 h, start 24 h 
   before ascent) if
   dexamethasone 
   contraindicated
• Rapid decent (>1,000 m)
• O2 (4–6 l/min.) or
hyperbaric chamber
• Nifedipine (20 mg 
   every 8 h)
• Dexamethasone (4 mg
   every 6 h)
AMS = acute mountains sickness; HAPE = high-altitude pulmonary oedema.
Scherrer_RL_A4_book_01_2011  15/03/2012  17:28  Page 68
High-Altitude Pulmonary Oedema – Novel Risk Factors, Treatment and Prevention
E U R O P E A N  R E S P I R A T O R Y  D I S E A S E 69
Subpopulations at Risk for High-Altitude
Pulmonary Oedema
Anatomical (congenital absence of the right pulmonary–artery,
pulmonary–artery occlusion from granulomatous mediastinitis)44,45 or
functional (Down syndrome)46,47 abnormalities that facilitate hypoxic
pulmonary hypertension, are risk factors for developing HAPE even at
relatively low altitude (1,500–2,500 m).
Patent Foramen Ovale
At high altitude, HAPE-prone subjects display exaggerated
hypoxemia before there is any evidence of alveolar fluid
accumulation. We found that intracardiac right-to-left shunting
contributes to this problem, because the prevalence of patent
foramen ovale (PFO) is more than four times greater in HAPE-prone
than in HAPE-resistant mountaineers.16 We suggest that, in 
HAPE-prone patients, the acute hypoxic pulmonary vasoconstriction
initiates a vicious cycle by causing right-to-left shunting across a
PFO, which in turn aggravates hypoxemia. This results in reduced
mixed venous oxygen tension, greater alveolar hypoxia and greater
pulmonary hypertension.48 In healthy adults, the prevalence of PFO is
20–25 %.49 However, so far there is no information available whether,
in this population, a PFO predisposes an individual to exaggerated
hypoxic pulmonary hypertension and HAPE. 
Down Syndrome (Trisomy 21)
Circumstantial evidence suggests that individuals with Down
syndrome are at risk for HAPE at relatively low altitude.46 In line with
this observation, Bolivian high-altitude natives with Down syndrome
display sustained pulmonary hypertension at high altitude and
appear to be at risk for re-entry HAPE (a particular form of HAPE
occurring in high-altitude dwellers when returning from a sojourn at
low altitude).47
Foetal Programming of Hypoxic Pulmonary
Hypertension
Epidemiological studies suggest that adverse events in utero
predispose individuals to cardiovascular and metabolic disease in
adulthood.50 For example, preeclampsia is the most frequent
complication of pregnancy. In mothers suffering from this problem,
circulating vasculotoxic factors [e.g. free radicals, soluble fms-like
tyrosine kinase 1 (sFlt-1), which binds placental growth factor (PlGF) and
vascular endothelial growth factor (VEGF)] produced by the diseased
placenta, induce vascular dysfunction and arterial hypertension.51–53 We
speculated that some of these factors might cross the placental
barrier and alter the regulation of vascular function in the fetus, which
might predispose that individual to a pathological response later in
life. To test this hypothesis, we measured pulmonary–artery pressure
in offspring of mothers with preeclampsia born and permanently living
at high altitude (La Paz, Bolivia, 3,600 m). We found that pulmonary–
artery pressure was approximately 30  % higher in offspring of
mothers with preeclampsia compared with control subjects living at
the same altitude.54 Vascular dysfunction was related to preeclampsia
itself (rather than to a genetic anomaly predisposing the mother to
preeclampsia and the offspring to vascular dysfunction), because
vascular function was perfectly normal in siblings of offspring 
of preeclampsia who were born after a normal pregnancy. The
preeclampsia-induced vascular dysfunction already has clinical
consequences at a young age, as evidenced by pulmonary
hypertension in approximately one third of these offspring of
preeclampsia-affected mothers living at high altitude,54 and by a high
prevalence of re-entry HAPE. Studies in experimental animals suggest
that the vascular dysfunction in offspring of preeclampsia is related to
an epigenetic mechanism.55 It is not yet known whether, among 
low-altitude residents, offspring of preeclampsia are at increased risk
for classical HAPE. 
Conclusions
High-altitude pulmonary oedema HAPE is a non-cardiogenic form of
pulmonary oedema usually occurring 36–72 hours after arrival at
high altitude in otherwise healthy individuals. Individual
predisposition is the most important risk factor for HAPE. Recent
data suggest that, in some cases, pathological events during the
foetal period involving epigenetic mechanisms contribute to this
predisposition. Excessive non-homogenous hypoxic pulmonary
vasoconstriction related to impaired pulmonary NO synthesis in
conjunction with defective alveolar fluid clearance related to
impaired transepithelial respiratory salt and water transport are the
main underlying mechanisms. Immediate descent is the treatment
of choice. If descent is not possible, low flow oxygen or a
hyperbaric chamber can be used. If oxygen is unavailable,
nifedipine (20 mg of extended release formulation every 8 hours) or
other drugs known to lower pulmonary artery pressure should be
administered. If neurological symptoms develop, dexamethasone
should be added. HAPE can be prevented by slow, graded ascent
(increase of the average sleeping altitude >2,500 m by <400 m/day).
In individuals who are susceptible to HAPE, prophylaxis with
dexamethasone or nifedipine, in addition to a slow ascent, can help
to prevent its reoccurrence. n
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